Abstract: PO1168
Evaluation of Biomarkers in Chronic Hemodialysis (HD) Patients Dialyzed with Optiflux High-Flux Dialyzers
Session Information
- Hemodialysis and Frequent Dialysis - 3
October 22, 2020 | Location: On-Demand
Abstract Time: 10:00 AM - 12:00 PM
Category: Dialysis
- 701 Dialysis: Hemodialysis and Frequent Dialysis
Authors
- Zhou, Meijiao, Fresenius Medical Care Renal Therapies Group, Waltham, Massachusetts, United States
- Ficociello, Linda, Fresenius Medical Care Renal Therapies Group, Waltham, Massachusetts, United States
- Costanzo, Mark, Fresenius Medical Care Renal Therapies Group, Waltham, Massachusetts, United States
- Mullon, Claudy, Fresenius Medical Care Renal Therapies Group, Waltham, Massachusetts, United States
- Kossmann, Robert J., Fresenius Medical Care North America, Waltham, Massachusetts, United States
Background
Optiflux® (OPTI) dialyzers are single-use, high-flux dialyzers available in the following sizes: F160NR (1.5 m2), F180NR (1.7 m2), F200NR (1.9 m2), and F250NR (2.5 m2). They are designed to enhance small and middle molecule clearance without increasing albumin loss. Epidemiologic data has shown low serum albumin (sALB) to be a marker of increased mortality risk in dialysis patients (pts). Thus, loss of albumin should be avoided especially in pts with low sALB. This retrospective study aimed to assess changes in biomarkers in pts dialyzed with Optiflux dialyzers for 6 months, including a subset of pts with low sALB levels at baseline.
Methods
976 in-center HD pts treated exclusively with Optiflux dialyzers for 6 months without liver disease, cancer, HIV, or history of drug abuse were analyzed in this study. Pre-HD labs at the first month of data collection (M1) and Month 6 (M6) were compared using paired t-test. A sub-analysis of pts with hypoalbuminemia (sALB ≤3.5mg/dL) at M1 was conducted. All analyses were performed separately for each dialyzer. Pts dialyzed with F200NR and F250NR were combined into 1 group.
Results
Mean biomarker levels during M1 and M6 are presented for the dialyzer groups (table). Most notably, significant increases of mean sALB and hemoglobin were observed in all groups. In the sub-analysis of pts with hypoalbuminemia at M1 (n=156), 87% of pts had increases in sALB by M6 (48/59=81.4% in F160NR, 82/92=89.1% in F180NR, and 5/5=100% in F200NR and F250NR) and 53.8% (84/156) achieved sALB >3.5 g/dL at M6.
Conclusion
During a 6-month follow-up, HD patients dialyzed with Optiflux dialyzers showed increases in serum albumin and hemoglobin while maintaining dialysis adequacy.
| Serum albumin (g/dL) | Hgb (g/dL) | spnPCR (g/kg/day) | UFV (L) | spKt/V | ||
| F160NR (n=310) | M1 | 3.80 | 10.66 | 1.03 | 2.13 | 1.80 |
| M6 | 3.89 | 11.05 | 1.07 | 2.20 | 1.81 | |
| Difference | 0.09 | 0.39 | 0.04 | 0.06 | 0.02 | |
| p-value | <0.0001 | <0.0001 | 0.01 | 0.08 | 0.36 | |
| F180NR (n=634) | M1 | 3.86 | 10.82 | 1.03 | 2.56 | 1.64 |
| M6 | 3.91 | 11.08 | 1.07 | 2.62 | 1.69 | |
| Difference | 0.05 | 0.26 | 0.04 | 0.06 | 0.05 | |
| p-value | <0.0001 | <0.0001 | 0.0006 | 0.03 | 0.002 | |
| F200NR and F250NR (n=32) | M1 | 3.82 | 10.91 | 1.10 | 3.65 | 1.54 |
| M6 | 3.93 | 11.28 | 1.05 | 3.56 | 1.54 | |
| Difference | 0.11 | 0.37 | -0.06 | -0.09 | -0.005 | |
| p-value | 0.02 | 0.03 | 0.05 | 0.40 | 0.87 |
Sp= single pool; nPCR = normalized protein catabolic rate; UFV= ultrafiltration volume
Funding
- Commercial Support –